Borroni, Edilio

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging

Ossenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 311

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

Leuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jögi, J., Palmqvist, S., Mattsson-Carlgren, N., et al. (2020) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 222

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

Leuzy, A., Smith, R., Cullen, N. C., Strandberg, O., Vogel, J. W., Binette, A. P., Borroni, E., Janelidze, S., Ohlsson, T., Jögi, J., et al. (2022) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 149

Increased basal ganglia binding of 18F‐AV‐1451 in patients with progressive supranuclear palsy

Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hägerström, D., Jögi, J., Borroni, E., Schöll, M., Honer, M., et al. (2017) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 118

Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression

Lindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 107

Identification of three novel radiotracers for imaging aggregated tau in Alzheimer's disease with positron emission tomography

Gobbi, L. C., Knust, H., Körner, M., Honer, M., Czech, C., Belli, S., Muri, D., Edelmann, M. R., Hartung, T., Erbsmehl, I., et al. (2017) · Journal of Medicinal Chemistry

Alzheimer's disease research and treatmentsRadiopharmaceutical Chemistry and Applications

Cited by 89

Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1 H -imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases

Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., et al. (2015) · Journal of Medicinal Chemistry

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 66

Tau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients

Smith, R., Cullen, N. C., Pichet Binette, A., Leuzy, A., Blennow, K., Zetterberg, H., Klein, G., Borroni, E., Ossenkoppele, R., Janelidze, S., et al. (2023) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 60